SELLAS Life Sciences Group, Inc. (SLS)

$2.2

-0.03 (-1.35%)
Rating:
Recommendation:
Buy
Symbol SLS
Price $2.2
Beta 1.805
Volume Avg. 0.23M
Market Cap 45.178M
Shares () -
52 Week Range 2.1-10.82
1y Target Est -
DCF Unlevered SLS DCF ->
DCF Levered SLS LDCF ->
ROE -166.08% Strong Sell
ROA -163.48% Strong Sell
Operating Margin -
Debt / Equity 432.52% Strong Buy
P/E -
P/B 8.69 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest SLS news


Dr. Angelos Stergiou
Healthcare
Biotechnology
NASDAQ Capital Market

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.